Company Overview: Lixte Biotechnology Holdings Inc

Industry News

7 Jun

Dr. Stephen Forman Joins Lixte Biotechnology’s Board of Directors

EAST SETAUKET, NY–(Marketwired – Jun 7, 2016) – Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, Director of the Hematologic Malignancies and Stem Cell Transplantation...

Read more

5 Jan

Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

EAST SETAUKET, N.Y., Jan. 5, 2016 /PRNewswire/ — Lixte Biotechnology Holdings, Inc. (LIXT) announced last week that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment...

Read more

6 Nov

Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity

EAST SETAUKET, N.Y., Nov. 6, 2015 /PRNewswire/ — Lixte Biotechnology Holdings, Inc. (LIXT) announced today that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented...

Read more

18 Sep

Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds

EAST SETAUKET, N.Y., Sept. 17, 2015 /PRNewswire/ — Lixte Biotechnology Holdings, Inc. (LIXT) (“Lixte” or the “Company”) has engaged the services of BioPharmaWorks LLC (“BioPharmaWorks”) to enhance the value of its clinical candidate portfolio. The scientific team at BioPharmaWorks ( provides expertise in multiple aspects of drug discovery, development and intellectual property....

Read more

18 Mar

Lixte Completes Private Placement Of Convertible Preferred Stock

 Lixte Biotechnology Holdings, Inc. (LIXT) announced today that one of its major shareholders has purchased $1,750,000 of Convertible Preferred stock. If fully converted, these shares would convert to 2,187,500 common shares at a per share price of $0.80. Lixte’s CEO, John S. Kovach, M.D., said, “Although Lixte has several...

Read more

18 Nov

Lixte Biotech: A Novel Approach to Boost Existing Cancer Therapies

WHITEFISH, MT / ACCESSWIRE / November 18, 2014 / Cellular signaling is a complex system of communication that governs basic cellular activities and coordinates cell actions. In many cases, errors in cellular information processing are responsible for diseases like cancer, autoimmune disorders, and diabetes. Researchers are attempting to understand...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address